Recently, based on the KEYNOTE-042 trial, the Food and Drug Administration (FDA) approved pembrolizumab as the first-line treatment for patients with advanced NSCLC expressing PD-L1 on at least 1% of tumor cells without EGFR or ALK genomic aberrations2. This evidence concerns the gene CD274 and neoplasm.